Many solid tumors contain an overabundance of phospholipid ethers relative to normal cells. Capitalizing on this difference, we created cancer-targeted alkylphosphocholine (APC) analogs through structure-activity analyses. Depending on the iodine isotope used, radioiodinated APC analog CLR1404 was used as either a positron emission tomography (PET) imaging ( 
INTRODUCTION
Selective delivery of diagnostic imaging and therapy agents to malignant tumors while sparing healthy tissues continues to be the major goal in cancer research and in clinical practice. Approaches to achieve this goal are reflected in therapeutic agents that are already approved or in development. Tumor-targeting vehicles based on antibodies, viruses, peptides, and nanoparticles have been used to deliver a wide range of "payloads" to cancer cells, including radioactive isotopes, imaging agents, oncolytic viruses, metals, and chemotherapeutic drugs (1) (2) (3) (4) (5) (6) (7) (8) . Currently available cancer therapy modalities offer either broad applicability across cancer types (for example, external beam radiation, surgery, cytotoxic drugs) or cancer selectivity based on higher expression of drug targets (genes) in cancer cell subpopulations compared to normal cells (for example, PML-RARa, BCR-ABL, c-kit, EGFR, ERBB2/ Her2/neu). Still, many cancers recur despite the initial disease control and therapeutic efficacy of many available cancer therapies. Recent evidence suggests that cancer recurrence likely involves failure to eradicate cancer cells that are relatively resistant to current therapies, such as cancer stem cells (or cancer stem-like cells) (9) (10) (11) .
A new therapeutic modality that minimizes damage to normal cells and combines cancer selectivity (including cancer stem cells) with a broad anticancer mechanism would represent a paradigm shift in cancer treatment. Naturally occurring phospholipid ethers (PLE) selectively accumulate in human cancer cells compared to normal cells (12) (13) (14) . Structure-activity relationship studies were previously performed at the University of Michigan with radioiodinated aryl PLE and a subset of alkylphosphocholine (APC) derivatives to see how alterations in molecular structure affected tumor retention of these compounds (15) (16) (17) (18) . These studies indicated that, for glycerol-derived PLE analogs, the stereochemistry at the sn-2 position of glycerol did not affect tumor uptake and retention in a rat sarcoma model. The length of the hydrophobic alkyl chain was discovered as another key characteristic that affected tumor retention of these compounds. Decreasing the alkyl chain length from 12 carbons (C 12 ) to C 7 resulted in little or no tumor accumulation, whereas increasing the chain length had the opposite effect, with C 15 and C 18 analogs showing delayed plasma clearance and enhanced tumor uptake. Furthermore, in the C 12 APC series, substitution of the choline part of the molecule with ethanol, ethanolamine, or 3,3-dimethyl-1-butanol reduced tumor uptake. From these studies, we found that the glycerol backbone was not required for tumor avidity, the alkyl chain must contain >11 methylene groups, and the position of iodine on the phenyl ring did not influence tumor uptake or specificity.
Ultimately, CLR1404 [18-(p-iodophenyl) octadecyl phosphocholine] was identified among nine PLE and APC analogs as the best tumorimaging agent in rodent models (18) . In follow-up pharmacologic toxicology studies, CLR1404 additionally exhibited low rodent toxicity and lower liver, kidney, bladder, and abdominal exposure compared to other derivatives. Moreover, replacement of iodine with optically active moieties yielded similar tumor selectivity and retention, suggesting bulk structural tolerance in that location. Therefore, we hypothesized that the CLR1404 chemical scaffold (Fig. 1 ) is uniquely well suited to deliver radioiodine isotopes and other reporters that are useful for either diagnostic imaging or therapy for a broad spectrum of solid tumors.
Unlike classical DNA-targeted cytotoxic agents, alkylphospholipids, including APC, target cellular and intracellular membranes (19) . When administered at therapeutic doses, alkylphospholipids inhibit phosphatidylcholine biosynthesis, interfere with lipid transduction pathways, and block the endoplasmic reticular transport of cholesterol, thereby ultimately disrupting cholesterol homeostasis and membrane lipid raft function (20) . Lipid rafts are specialized plasma membrane microdomains rich in cholesterol and sphingomyelin (21) , which spatially organize signaling pathways and regulate cell proliferation and survival (apoptosis) (22) . Lipid rafts, which are more abundant in cancer cells relative to normal cells (23) , serve as cellular portals of entry for CLR1404 and other alkylphospholipids into tumors.
Here, we report results of in vitro and in vivo testing with radioisotopelabeled CLR1404 for diagnostic imaging ( 124 I-CLR1404) and for cancer therapy ( 131 I-CLR1404), as well as imaging data with the fluorescent analog CLR1501, in a wide variety of tumor models. We also present first-in-human imaging results showing that CLR1404 has tumor-targeting and retention properties in cancer patients. CLR1404 represents a new class of synthetic APC analogs to be used for broad-spectrum, tumorselective molecular imaging and therapy in human cancers.
RESULTS
Preferential uptake and retention of APC analogs in cancer cell lines CLR1501, a fluorescently labeled CLR1404 analog (Fig. 1) , was administered to seven different cancer cell lines (renal, colorectal, glioma, ovarian, pancreatic, melanoma, and prostate) and a normal human skin fibroblast line in vitro. Twenty-four hours later, CLR1501 exhibited five-to ninefold preferential uptake in these cancer cell lines in vitro compared to normal fibroblasts ( Fig. 2A and fig. S1 ). Retained CLR1501 was associated with plasma and organelle membranes. Cancer-selective localization of APC analogs was also observed in a coculture of human prostate carcinoma cells (PC-3) and a primary normal human skin fibroblast cell line treated with CLR1501 for 24 hours and imaged with confocal microscopy (Fig. 2B) .
To further examine cancer cell-selective targeting, three pairs of patient-matched normal and cancer cell lines were treated with 125 I-CLR1404. The osteosarcoma cell line 704.T is from the same patient as the normal skin cell line, 704.sk. There was a 2.8-fold increase in the observed 125 I-CLR1404 uptake by the osteosarcoma cell line compared to normal, patient-matched cells (Fig. 2C) . Similarly, for two nonsmall cell lung cancer (NSCLC) patient cell lines, H2122 and H1395, there were significant increases in 125 I-CLR1404 uptake compared to their patient-matched normal cell lines BL2122 and BL1395 (derived from their respective B-lymphoblast cell lines), respectively.
Next, we visualized the kinetics of CLR1501 entry into PC-3 cells over the course of 1 hour. CLR1501 entered cells via plasma membranes and collected in membrane-bound vesicles, eventually localizing to membranes of cytoplasmic organelles (movie S1). Maximal uptake of 125 I-CLR1404 was reached after 48 hours in normal skin fibroblasts compared with 24 hours in human NSCLC cells, with the final levels S3 ). This supports the hypothesis that CLR1404 uses lipid rafts as portals of entry into cancer cells. Notably, higher filipin III concentrations are cytotoxic, and therefore, complete lipid raft ablation (and presumably complete CLR1404 analog uptake inhibition) could not be accomplished.
Because of their emerging role in cancer progression and relapse, cancer stem cells were also analyzed for CLR1404 uptake. Human glioblastoma (GBM) stemlike cell (GSC) lines were isolated from patient surgical specimens. Six GSC lines (12.1, 22, 33, 44, 99 , and 105) were validated for enhanced expression of stem cell markers [cluster of differentiation 133 (CD133) and nestin] and multilineage potential (neuronal and glial) (11, 24) . Patientmatched, serum-cultured GBM cell lines (serGBM) 22, 33, and 99 were established from the same specimens used for establishing the GSC lines. The stem-like properties of GSCs are rapidly lost in serum culture, so serGBM lines served as a model of non-GSC GBM cells. Both GSCs and serGBM cells exhibited enhanced CLR1501 uptake compared to normal human astrocytes and fetal human neural stem cell (NSC) lines (Fig. 3, A and B) . Flow cytometry confirmed greater uptake for GSC and serGBM lines compared to astrocytes (Fig. 3B) .
Although enriched for GSCs, GBM spheres consist of a mixture of GSCs, as well as non-GSCs. Therefore, we sought to further verify that GSCs are labeled with CLR1404 analogs by colabeling with the GSC marker CD133. CLR1501 uptake was seen in both CD133 + and CD133 − GSCs; however, significantly higher fluorescence was found in CD133 + GSCs compared to CD133 + NSCs (Fig. 3C and fig.  S4 ). These data indicate that APC analogs preferentially label all GBM cells, including cancer stem-like cells, with minimal retention by normal neural and neural stem cells.
Selective uptake and retention of APC analogs in tumors Radioiodinated 124 I-CLR1404 was tested in subcutaneous and orthotopic xenografts (table S1) .
In vivo cancer stem cell labeling with CLR1501 was also demonstrated in GSC-derived orthotopic xenografts in mice. After MRI verification of brain tumor, CLR1501 administered intravenously labeled all tumor cells (Fig. 5, A and B) , including GSCs that stained positive for nestin, Olig2, and CD15/SSEA-1 ( + cells may be retained in the serum-cultured U251 glioma line (25) , and serum-cultured tumor lines may reexpress CD133 after in vivo engraftment (26) . Therefore, the presence of CD133 + U251 cells within mouse brain tumor xenografts is not unexpected.
Benign or premalignant tumors showed very little or no uptake in animal models (table S1). Moreover, unlike I-CLR1404 was sufficient to provide statistically significant tumor growth suppression and survival benefit in these cancer models when compared to control animals treated with an equivalent mass dose of nonradioactive CLR1404. Antitumor efficacy was pronounced in terms of the degree and duration of growth suppression in the renal, colorectal, ovarian, prostate, and triple-negative breast cancer models (Fig. 6 ). In the relatively radioresistant uterine sarcoma and glioma models, two injections of Preliminary results were obtained in an NSCLC patient without neurological symptoms using 124 I-CLR1404 PET/CT. Imaging revealed three previously unknown brain lesions highly suspicious for metastases that were subsequently confirmed with gadolinium-enhanced MRI (Fig. 7A) . Clinical management of this patient was then altered to include brain radiotherapy.
Although MRI revealed the suspected grade IV glioma in a patient (Fig. 7, B and C) , high tumor-to-normal brain ratios after administration of 124 I-CLR1404 also permitted easy tumor visualization (Fig. 7D) . In another example, a tumor/brain ratio of 30 on PET was obtained 2 days after injecting 5 mCi of 124 I-CLR1404 in a patient with grade II/III astrocytoma ( fig. S8 ). Tumor uptake and prolonged retention were also demonstrated using SPECT (single-photon emission computed tomography)/CT imaging in a colorectal cancer patient with known liver and lung metastases 21 days after injection of 131 I-CLR1404 ( fig. S9) . We also successfully isolated and expanded GSCs (line 107) from a surgical GBM specimen obtained after preoperative 124 I-CLR1404 injection (Fig. 7D) . After implantation of 107 GSCs into immunodeficient mice, resultant tumor xenografts were visualized after injection of CLR1502 (near-infrared CLR1404 analog) (Fig. 7E) . Highly invasive glioma xenograft phenotypes were also verified after histological processing (Fig. 7, F to I ).
DISCUSSION
We demonstrate in vitro and in vivo selective uptake of APC-based imaging and therapeutic agents by a wide range of malignant cells. For in vivo studies, both rodent cancer models and human patients were studied using analogs containing either a PET-imaging isotope ( Uptake of the CLR1404 chemical scaffold into cancer cells appears to partially involve interaction with lipid raft regions of the plasma membrane (22, (30) (31) (32) . This hypothesis was supported in this study by decreased uptake of 125 I-CLR1404 after pretreatment of human cancer cells with the lipid raft disruptor, filipin III. A lipid raft-based mechanism for uptake into cancer cells has also been reported for other alkylphospholipids (21) . Lipid rafts and cholesterol (a key raft constituent) are more abundant in cancer cells compared to normal cells (23) , and may partially account for CLR1404's cancer cell selectivity. CLR1404 interaction with lipid rafts may also explain the finding that CLR1404 uptake was significantly higher in CD133 + GSCs versus matched CD133 − non-GSCs (in four of five sphere-cultured lines), because CD133 was demonstrated to localize to cholesterol-rich lipid raft microdomains (33). Control animals were administered a mass-equivalent CLR1404 dose (n = 6). Data are mean tumor volumes ± SEM. P values for tumor growth curves determined by one-way repeated-measurement ANOVA. P values for survival curves were constructed by Kaplan-Meier method and analyzed via log-rank test.
PET/CT imaging of a wide range of in vivo rodent cancer models using CLR1404 derivatives showed cancer-selective uptake and retention. Notably, these models include genetically engineered tumors and spontaneous tumors, in addition to human tumor xenograft models (subcutaneous and orthotopic). Exploiting the sensitivity and quantification properties of PET, 124 I-CLR1404 imaging revealed both primary cancers and metastatic lesions in these models. Malignant tumor selectivity was confirmed in tissue distribution studies with 125 I-CLR1404 in multiple animal tumor models (18) .
Initial imaging results obtained with 124 I-CLR1404 in a small number of human lung and brain cancer patients confirmed tumor uptake and retention properties seen in preclinical models. Tumor conspicuity was particularly marked because of the combination of high brain tumor uptake (primary gliomas and brain metastases) and low normal brain background radioactivity. I-CLR1404 combines a powerful and widely applicable therapeutic modality (radiation) with a broadspectrum cancer-targeting mechanism.
To better understand and translate these APC analogs to clinical use, other questions need to be addressed. Cancer and cancer stem cellspecific uptake and retention of CLR1404 analogs in other cancer types need to be verified, beyond the GSC and GBM data in this study. For central nervous system (CNS) tumor therapy, the blood-brain barrier (BBB) permeability of CLR1404 analogs remains unknown. Primary or metastatic brain tumors often alter BBB permeability and other vascular properties (34) , which may enhance the permeability of CLR1404 analogs. Minimal uptake and retention in normal brain both in animal models and in humans suggest a low CLR1404 analog permeability across intact BBB; alternatively, normal neural tissues may also metabolize CLR1404 analogs more rapidly than other body tissues. Optimal dosing and imaging parameters for human imaging and therapy for different cancers (that is, primary versus metastatic, body versus brain tumors), and relative to patient weight, age, or other physical parameters, need to be investigated.
In conclusion, the APC analog-based scaffold exemplified by CLR1404 can act as a cancer cell and cancer stem cell-targeted vehicle for diagnosis and therapy in many types of malignant tumors. They may discriminate tumor recurrence versus pseudoprogression, a difficult task with current 
MATERIALS AND METHODS

Study design
Our goal was to evaluate the use of CLR1404 APC analogs in tumor imaging and therapy. We tested radioiodinated and fluorescent CLR1404 analogs (Fig. 1) for tumor-specific labeling and retention properties in vitro and in vivo in 57 different tumor cell lines and xenograft and transgenic tumor models, and also tested whether tumor labeling is altered by lipid raft disruption. Using six distinct human GSC lines, we tested the ability of APC analogs to label both cancer stem cells and serum-cultured, nonstem cells from GBM. Then, we showed the efficacy of 131 I-CLR1404 therapy in animal tumor models of eight different human cancers. We also evaluated the use of APC analogs in human cancer imaging in adult patients with different types of primary and metastatic cancers throughout the body and brain (table S2) through the following clinical trials registered on clinicaltrials.gov: NCT01516905, NCT01540513, NCT01495663, NCT00582283, and NCT01898273.
Synthesis and radioiodination of CLR1404
Synthesis of 18-(p-iodophenyl)octadecyl phosphocholine was previously reported (18) . Radioiodination was achieved in 70% isolated radiochemical yield via isotope exchange with I-sodium iodide (PerkinElmer) (35) . After purification (>99% radiochemical purity) and accurate mass quantification by high-performance liquid chromatography [normal phase, isocratic isopropanol/hexanes/ water (13:10:2)], the radiopharmaceutical was dissolved in absolute ethanol (50 to 500 ml) and Tween 20 (0.1 ml/mg of compound). The ethanol was removed under vacuum, and the residue was dissolved in sterile water to give a final solution containing no more than 0.4% Tween 20. Sterilization is achieved by filtration through a sterile 0.2-mm filter unit. Injection solutions are tested for pyrogens using the Limulus Amebocyte Lysate test kit. Synthesis of the other analogs, CLR1501 and CLR1502, is shown in fig. S10 and described in Supplementary Methods.
Cell culture
Human cancer cell lines were purchased from the American Type Culture Collection (ATCC). They included the following: Caki-2 (renal; clear cell carcinoma), HCT-116 (colorectal carcinoma); MES-SA/Dx5 (uterine sarcoma) [all maintained in McCoy's 5a medium supplemented with 10% fetal bovine serum (FBS)], Ovcar-3 (ovarian adenocarcinoma) [maintained in RPMI medium supplemented with 20% FBS], U87-MG (glioma) [maintained in minimum essential medium supplemented with 10% FBS], Mia Paca-2 (pancreatic carcinoma) (maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS), PC-3 (prostate carcinoma) (maintained in F-12K medium supplemented with 10% FBS), MDA-MB-231 (triple-negative mammary gland adenocarcinoma) (maintained in Leibovitz's medium supplemented with 10% FBS), and A549 (non-small cell lung carcinoma) (maintained in F-12 medium supplemented with 10% FBS). Normal human skin fibroblasts were purchased from ATCC and grown in Fibroblast Basal Medium PCS-201-030 supplemented with serum-free kit (Fibroblast Growth Kit-Serum-Free PCS-201-040). All media (except for MDA-MB-231 cell line) also contained penicillin (100 U/ml) and streptomycin (100 µg/ml) and were maintained at 37°C with 5% CO 2 in air.
Fluorescent staining and confocal imaging
All cells were maintained at 37°C in appropriate medium supplemented with 10% FBS and 5% CO 2 . Before imaging, the cells were removed from flasks with 0.25% trypsin and were allowed to grow overnight on the microslides VI (Ibidi). The next day, the cells were washed with phosphate-buffered saline (PBS) and were incubated with either 5 or 7.5 µM (as indicated) of CLR1501 in appropriate serum-free medium for 24 hours. CLR1501 was formulated with 0.4% of Polysorbate 20, 2% of ethanol, and saline. After washing thoroughly with PBS, the cells were imaged using Bio-Rad Radiance 2100 MP Rainbow laser scanning/multiphoton confocal microscope using a 1-s exposure time. Alternatively, cells were visualized using a Nikon A1R confocal microscope (Keck Laboratory, University of Wisconsin-Madison). The emission signal of CLR1501 was detected using Alexa Fluor 488 filters (ex/em 480/520 nm).
Cell culture videography PC-3 cells, a human prostate adenocarcinoma, were maintained in F12 medium supplemented with 10% FBS and 1% penicillin and streptomycin. The cells were plated overnight in MatTek petri dish. The next day, the cells were washed with PBS and stained with Image-IT LIVE Mitochondrial and Nuclear Labeling Kit, which provides two stains-red fluorescent MitoTracker Red CMXRos dye and blue-fluorescent Hoechst 33342 dye-for highly selective mitochondrial and nuclear staining (Invitrogen). The image acquisition was performed with an A1R Nikon confocal system and was initiated when 5 mM CLR1501 was added to the petri dish; the video (movie S1) was acquired for 1 hour.
Matched cell lines
Three sets of normal human and cancer cell lines were purchased from ATCC. The lung adenocarcinoma cell line (NCI-H1395) and a normal B-lymphoblast cell line derived from the same patient (NCI-BL1395) were both cultured in RPMI 1640 medium supplemented with 10% FBS. The NSCLC cell line (NCI-H2122) and a normal B-lymphoblast cell line derived from the same patient (NCI-BL2122) were also both cultured in RPMI 1640 medium supplemented with 10% FBS. The osteosarcoma cell line (Hs 704.T) and a normal skin fibroblast cell line derived from the same patient (Hs 704.sk) were both cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. Uptake and retention of 125 I-CLR1404 at 24 hours were determined as described above.
Isolation of GSCs
GSCs were isolated and propagated using marker neutral, serumfree sphere culture in stem cell medium following protocols previously reported (11, 24) , under an approved institutional review board protocol. Using this methodology, we isolated and fully validated six GSC lines, five primary and one recurrent: 12.1 (recurrent), 22, 33, 44, 99, and 105. These different GSC lines exhibit varied molecular and biological properties (24) . Human cortex fetal NSCs were maintained as previously described (36) . SerGBM and normal human astrocytes were maintained in medium containing 10% FBS.
Human tumor xenograft models All described animal studies were performed according to animal protocols approved by the Institutional Animal Care and Use Committee. Female athymic nude mice (Hsd:Athymic Nude-Foxn1nu or Crl:NU-Foxn1nu, Charles River Laboratories) about 4 to 5 weeks of age, 16 to 18 g (n = 6), were used for human tumor xenograft studies. Mice were anesthetized with isoflurane and injected subcutaneously with viable tumor cells in 100 µl of Dulbecco's PBS (or, for glioma cells, 50 ml of PBS) into the right flank. Inoculum sizes were 1 × 10 6 (for renal, ovarian, glioma, pancreatic, prostate, and NSCLC models), 2 × 10 6 (for colorectal and uterine models), or 3 × 10 6 (breast).
Radiotherapy of tumor-bearing mice Both 131 I-CLR1404 and the control, CLR1404, were formulated with 0.08% Polysorbate 20 NF, 0.4% sodium ascorbate USP, 5% ethanol, 200 proof, USP in 0.9% sodium chloride injection, USP. The formulation for the glioma and breast models used 25% ethanol. At the time of dose preparation, the drug formulation was diluted 1:5 in 0.9% sodium chloride to reduce the ethanol concentration to about 5%. For assessment of CLR1404, formulation was in 0.08% of Tween 20, 0.4% sodium ascorbate USP, 5% ethanol in 0.9% NaCl for injection, USP. The control was 0.9% NaCl for injection, USP. Treatment with test agents via tail vein injection (150 ml of dosing volume) was initiated when tumors had reached a predetermined size range in mm 3 (50 to 150 for uterine, pancreatic, glioma, and breast; 50 to 230 for ovarian; 100 to 150 for NSCLC; 100 to 250 for renal and colorectal; and 150 to 300 for prostate). Once tumors reached these target ranges, animals were randomly assigned to treatment groups (day 0). In 131 I-CLR1404-treated animals, the approximate radioactivity dosed per mouse (administered on day 0 only, unless otherwise indicated) and the number of mice per group were as follows: renal: 110 mCi, n = 6; colorectal: 110 mCi, n = 6; uterine: day 0, 130 mCi, and day 20, 145 mCi, n = 6; ovarian: 115 mCi, n = 5; glioma: days 0 and 7, 100 mCi, n = 8; pancreatic: 125 mCi, n = 5; prostate: day 7, 100 mCi, n = 6; breast: day 7, 100 mCi, n = 8 to 9. Control animals (n = 6) were administered 0.0038 mg of CLR1404 (~0.19 mg/kg, an amount equivalent to that represented by a 100-mCi dose of 131 I-CLR1404) on day 0 only. In all therapy studies, mice were given potassium iodide at a concentration of 0.1% in their drinking water to block uptake of any free iodide in the drug formulation [with the addition of 0.4% (w/v) sweetener (Sweet and Low) to aid palatability] starting 3 days before the estimated day 0 for a total of 17 days. All mice were given free access to food and water throughout each study. The nonradioactive animals were housed in groups of three to four in cages and well separated from the radioactive animal cages. Radioactive animals were housed individually with lead shielding between cages.
Tumor growth was assessed by measuring two perpendicular tumor diameters using a caliper, and the resulting measurements were used for estimating tumor volume [tumor volume = (width 2 × length × p)/6)]. Survival analysis was based on the date of death of the animal, or the date the animal was sacrificed based on either being found in moribund condition or the tumor size reaching >2000 mm 3 .
In vivo micro-PET/CT imaging Mice were anesthetized with isoflurane (2%) and scanned in a prone position on a Siemens Inveon micro-PET/CT scanner (Siemens Preclinical Systems) at various time points (ranging from 6 hours to 10 days) after injection of . Corrections of normalization, dead time, scatter, and attenuation were applied using the system software and the co-registered CT scan. PET data were quantified using a calibration specific to 124 I. Image analysis, including region of interest quantification and co-registration of multiple time points, was performed with the Inveon Research Workplace (Siemens Preclinical Systems) and Amira (Visage Imaging Inc.).
Micro-PET tumor imaging with 124 I-CLR1404 and 18 F-FDG in the presence of inflammation is described in Supplementary Methods. GSC orthotopic xenograft model All described animal studies were performed according to animal protocols approved by the Institutional Animal Care and Use Committee. GSC-derived orthotopic xenografts were initiated as previously described (11, 24) . Cells were stereotactically injected into the right striatum of anesthetized nonobese diabetic severe combined immunodeficient mice at the following coordinates referenced from bregma: 0 mm anteroposterior, +2.5 mm mediolateral, and −3.5 mm dorsoventral. Mice were then euthanized upon tumor verification by MRI or onset of neurological symptoms, and brain was processed for histological analysis.
In vivo optical studies Fluorescent analog CLR1501 (green) or CLR1502 (near-infrared) was injected (1 mg) intravenously (lateral tail vein) or retro-orbitally into anesthetized (isoflurane) mice bearing orthotopic GSC-derived xenografts. After 4 days, animals were euthanized and brains were excised, fixed, frozen-sectioned, and immunohistochemically stained as described above. Confocal microscopy was then performed as described above. CLR1502 was visualized using IVIS Spectrum system (PerkinElmer/Xenogen). I-CLR1404, planar whole-body images at multiple time points were acquired on a dual-head scanner (Infinia Hawkeye, General Electric) using a scan speed of 10 cm/s, 256 × 1024 matrix, peak set at 364 keV ± 15% and scatter peaks of 312 keV ± 15% and 424 keV ± 15%, high energy all-purpose collimator, and display bone dual density. SPECT/CT images of specific regions of interest were acquired at multiple time points on a SPECT/CT scanner (Infinia Hawkeye, General Electric) using 128 × 128 matrix, 120 projections, 3°per stop, 30 s per stop, with peak set at 364 ± 15% and scatter peaks of 312 ± 15% and 424 ± 15%. The CT settings are helical using a pitch of 1.9, interval 4.42 mm, voltage 140 kV, current 2.5 mA, matrix 512 × 512, filter soft, and pixel 1.10 mm. Processing was performed with Volumetrix MI.
Human PET/CT imaging
Statistics
One-way repeated measurement ANOVA (SigmaStat v3.5, Systat Software Inc.) was performed to analyze tumor growth in control and treatment groups. Tumor growth was plotted until one animal from either group died (to maintain appropriate statistical analysis). A log-rank statistical analysis was used for comparison of survival benefit between groups. All comparisons of multiple groups were performed with one-way ANOVA with Bonferroni post hoc testing. P < 0.05 was considered significant.
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